These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 8656247

  • 1. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ.
    J Clin Oncol; 1996 Jun; 14(6):1787-97. PubMed ID: 8656247
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF.
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [Abstract] [Full Text] [Related]

  • 3. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
    Tschmelitsch J, Barendswaard E, Williams C, Yao TJ, Cohen AM, Old LJ, Welt S.
    Cancer Res; 1997 Jun 01; 57(11):2181-6. PubMed ID: 9187118
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.
    Yu B, Carrasquillo J, Milenic D, Chung Y, Perentesis P, Feuerestein I, Eggensperger D, Qi CF, Paik C, Reynolds J, Grem J, Curt G, Siler K, Schlom J, Allegra C.
    J Clin Oncol; 1996 Jun 01; 14(6):1798-809. PubMed ID: 8656248
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice.
    Barendswaard EC, Scott AM, Divgi CR, Williams C, Coplan K, Riedel E, Yao TJ, Gansow OA, Finn RD, Larson SM, Old LJ, Welt S.
    Int J Oncol; 1998 Jan 01; 12(1):45-53. PubMed ID: 9454885
    [Abstract] [Full Text] [Related]

  • 9. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM.
    Cancer Res; 1996 Apr 15; 56(8):1805-16. PubMed ID: 8620497
    [Abstract] [Full Text] [Related]

  • 10. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
    DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, McGahan JP, Salako Q, Shen S, Lewis JP.
    J Clin Oncol; 1998 Oct 15; 16(10):3246-56. PubMed ID: 9779698
    [Abstract] [Full Text] [Related]

  • 11. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L.
    J Nucl Med; 1995 Apr 15; 36(4):586-92. PubMed ID: 7699446
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G.
    Clin Cancer Res; 1995 Dec 15; 1(12):1447-54. PubMed ID: 9815943
    [Abstract] [Full Text] [Related]

  • 13. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, Lorf T, Post S, Wörmann B, Hiddemann W, Ringe B, Becker W.
    Anticancer Res; 1999 Dec 15; 19(4A):2427-32. PubMed ID: 10470170
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M, Swayne LC, Sharkey RM, Dunn R, Rubin AD, Herskovic T, Goldenberg DM.
    Gynecol Oncol; 1997 Dec 15; 67(3):259-71. PubMed ID: 9441773
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 15; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer.
    Street HH, Goris ML, Fisher GA, Wessels BW, Cho C, Hernandez C, Zhu HJ, Zhang Y, Nangiana JS, Shan JS, Roberts K, Knox SJ.
    Cancer Biother Radiopharm; 2006 Jun 15; 21(3):243-56. PubMed ID: 16918301
    [Abstract] [Full Text] [Related]

  • 19. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.
    Welt S, Ritter G, Williams C, Cohen LS, Jungbluth A, Richards EA, Old LJ, Kemeny NE.
    Clin Cancer Res; 2003 Apr 15; 9(4):1347-53. PubMed ID: 12684403
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.